Acist Medical Systems Announces Japanese Ministry of Health Approval at the Kurashiki Live Demonstration Course.Business Editors & Healtcare Writers EDEN PRAIRIE Eden Prairie A city of eastern Minnesota, a residential suburb of Minneapolis. Population: 57,300. , Minn.--(BUSINESS WIRE)--March 7, 2000 Acist Medical Systems' CL100 Automated Contrast Injection system received Japanese Ministry of Health approval on February 25, 2000. Approval was announced at the 9th Live Interventional Cardiology interventional cardiology Cardiology The subspecialty of cardiology dedicated to the diagnosis, medical and mechanical therapy, pre- and post-procedure management of adult patients with acute and chronic forms of cardiovascular disease amenable to catheter-based Demonstration Course held annually in Kurashiki, Japan where 1,050 participants from all over Japan were introduced to the product. Dr. Kazuaki Mitsudo, Director of Cardiology for Kurashiki Central Hospital, performed 18 cases in the two-day demonstration course and highlighted the use of the ACIST device in all interventional procedures during his international acclaimed live demonstration course. "After only a couple of cases I grew comfortable with the variable injection feature and quickly appreciated the reductions in contrast volumes, fluoroscopy fluoroscopy /flu·o·ros·co·py/ (fldbobr-ros´kah-pe) examination by means of the fluoroscope. fluo·ros·co·py n. Examination by means of a fluoroscope. Also called radioscopy. use, and overall procedure time" said Dr. Mitsudo. "With the ACIST hand controller, I was able to remain focused on the job at hand, not on the usual tasks associated with injecting contrast. The ACIST enables a single operator to perform the entire PTCA PTCA abbr. percutaneous transluminal coronary angioplasty PTCA Percutaneous transluminal coronary angioplasty, see there procedure," he added. Dan Gladney, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Acist Medical Systems, said that the timely approval of the ACIST System in Japan was, "A vital step in developing the ACIST product as the standard in contrast delivery for all interventional procedures worldwide. The opportunity to work closely with key opinion leaders of interventional cardiology both in Japan and around the world has allowed us to remain focused on the added value Added value in financial analysis of shares is to be distinguished from value added. Used as a measure of shareholder value, calculated using the formula:
The CL100 and related disposables received FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. clearance in 1998. Since then the ACIST has enjoyed consistent growth in its installed base. By allowing physicians to do away with cumbersome manual syringes and stopcocks, as well as the additional set up of traditional power injectors, the ACIST system's unique design gives interventional cardiologists the freedom to control the precise flow of contrast delivery with the use of a simple hand controller. Acist Medical Systems is a privately-held corporation founded in 1991 that has developed a new system to improve the delivery of contrast agents during angiographic procedures. Additional information about Acist Medical Systems is available on the company's website at http://www.acistmedical.com or by calling 952-941-3507. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion